Clinical Trials Logo

Filter by:
NCT ID: NCT05143073 Completed - Clinical trials for Alcohol Use Disorder

Understanding Genetic Risk for Alcohol Use Disorder

Start date: November 15, 2021
Phase: N/A
Study type: Interventional

The purpose of this study is to evaluate an online educational tool that will help individuals better understand alcohol use disorder, risk factors, and genetic risk information and to better understand participant's beliefs regarding alcohol use disorder. This study does not involve genetic testing. Investigators will not be giving participants any personalized genetic feedback as part of the study; however, investigators will ask participants to imagine that they receive different hypothetical genetic risk scores and respond to survey items.

NCT ID: NCT05143047 Completed - Clinical trials for Medication Management

Discharge Medication Counseling in Hospitalized Children

Start date: June 25, 2021
Phase: N/A
Study type: Interventional

Our objective is to design and test the efficacy of a health-literacy-informed discharge medication counseling intervention in the inpatient setting to reduce medication dosing errors and improve adherence in hospitalized children discharged on a new liquid medication.

NCT ID: NCT05143008 Completed - Pregnancy Related Clinical Trials

A Pilot Study to Evaluate an Intervention for Gestational Weight Gain

Start date: August 13, 2015
Phase: N/A
Study type: Interventional

The purpose of this study is to enable the investigator to conduct proof of concept work related to the feasibility, acceptability, initial efficacy and mechanisms of action (focusing on maternal and infant modifiable factors) for a novel self-management intervention for pregnant women.

NCT ID: NCT05142774 Completed - Atopic Dermatitis Clinical Trials

Long Term Extension Study of Tapinarof Cream, 1% for Subjects With Atopic Dermatitis

Start date: October 28, 2021
Phase: Phase 3
Study type: Interventional

This is an open-label, long-term multicenter, study to evaluate the safety and efficacy of topical tapinarof cream, 1% in subjects with atopic dermatitis. Subjects in this study have completed treatment in one of two Phase 3 pivotal studies (DMVT-505-3101 or DMVT-505-3102) or completed treatment in the DMVT-505-2104 study, or directly enrolled into this study. This study will consist of up to 48 weeks of treatment and a 1 week safety follow-up period.

NCT ID: NCT05142761 Completed - Clinical trials for Ventral Incisional Hernia

Tension in Posterior Component Separation for Abdominal Wall Reconstruction

Start date: December 2, 2021
Phase:
Study type: Observational [Patient Registry]

The purpose of this study is to measure the changes in tension after each release in a standard posterior component separation during abdominal wall reconstruction.

NCT ID: NCT05142436 Completed - Smoking Clinical Trials

BAT3221032: A Study to Evaluate the Effects of Switching From Cigarette Smoking to Using One of Five Variants of a Heated Tobacco Product on Biomarkers of Exposure and Biomarkers of Potential Harm in Healthy Subjects

Start date: January 13, 2022
Phase: N/A
Study type: Interventional

This is a randomized, controlled, multi-center, open-label, 8-cohort parallel group study to assess changes in select biomarkers of exposure (BoE) and biomarkers of potential harm (BoPH) in generally healthy smokers switching to the study investigational products (IPs), compared to subjects who continue to smoke, undergo smoking abstinence, or have never smoked.

NCT ID: NCT05142306 Completed - Clinical trials for SARS-CoV-2 Infection

A COVID-19 Study to Evaluate Safety and PK of COVID-HIG Administered Through IM, SC, or IV Routes as a Single Dose Regimen to SARS-CoV-2 Uninfected Adults

Start date: December 7, 2021
Phase: Phase 1
Study type: Interventional

The primary objectives of this open-label trial were to evaluate the safety and pharmacokinetics (PK) of Anti-SARS-CoV-2 Immunoglobulin (Human) Investigational Product (COVID-HIG) administered intramuscularly (IM), subcutaneously (SC), or intravenously (IV) as a single dose in healthy adults 18-59 years of age with body mass index ≤35 kg/m^2. Prior studies examined IV administration, and the secondary objective of the present study was to compare PK among the three administration routes. No placebo group was included in the phase 1 randomized design. The exploratory objective was to evaluate disease severity in participants that became positive for SARS-CoV-2.

NCT ID: NCT05141903 Completed - Healthy Adults Clinical Trials

Dietary Supplement With and Without a Probiotic and/or Antibiotic

Start date: September 21, 2021
Phase:
Study type: Observational

Complex oligosaccharides can alter the gut microbiome by aiding in the growth of certain organisms, and possibly, inhibiting others. The synergy with a probiotic may enhance gastrointestinal colonization.

NCT ID: NCT05141708 Completed - Breast Neoplasms Clinical Trials

Treatment Patterns and Clinical Outcomes Among Talazoparib-Treated Adults With HER2-Negative mBC With gBRCA1/2m

Start date: December 17, 2021
Phase:
Study type: Observational

This non-interventional retrospective study will describe real-world treatment patterns and clinical outcomes among adults with HER2-negative metastatic breast cancer with germline BRCA1/2 mutations who initiated talazoparib as a first or later line of therapy. Patients will be identified from the Flatiron Electronic Health Record database.

NCT ID: NCT05141669 Completed - Multiple Sclerosis Clinical Trials

Impact of Fingolimod Adherence on Outcomes

Start date: May 18, 2020
Phase:
Study type: Observational

This study was a retrospective observational claims data study of commercial and Medicare Advantage with Part D (MAPD) patients initiating fingolimod.